
    
      The is a prospective, randomized two-arm, and multicenter study. To compare the efficacy and
      safety of low-dose ruxolitinib combined with calcineurin and methotrexate vs. calcineurin
      plus methotrexate and mycophenolate mofetil as graft versus host disease prophylaxis for
      HLA-haploidentical hematopoietic stem cell transplantation in low-dose antithymocyte globulin
      (ATG) system.
    
  